首页> 外文期刊>Human Genetics >Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas
【24h】

Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas

机译:Milroy病和其他原发性淋巴水肿中VEGFR3和VEGFC编码区的分析

获取原文
获取原文并翻译 | 示例
           

摘要

Milroy disease (hereditary lymphoedema type I, MIM 153100) is a congenital onset primary lymphoedema with autosomal dominant inheritance. Mutations in the gene, vascular endothelial growth factor receptor 3, VEGFR3 (FLT4), are known to cause Milroy disease, but there is uncertainty about the prevalence of VEGFR3 mutations in patients with primary lymphoedema and more specifically in those with a phenotype that resembles Milroy disease. This study aims to address this issue and thereby delineate the Milroy disease phenotype. Fifty-two patients with primary lymphoedema were analysed for mutations in the coding regions of VEGFR3. Patients were divided into four groups: Typical Milroy disease with family history (group I), typical Milroy disease with no family history (group II), atypical Milroy disease (group III), and complex primary lymphoedema (group IV). Results demonstrated that with rigorous phenotyping the likelihood of detecting VEGFR3 mutations is optimised. Mutation prevalence is 75% in typical Milroy patients with a family history (group I) and 68% if positive family history is not a diagnostic criterion. A positive family history is not essential in Milroy disease. The likelihood of detecting VEGFR3 mutations in patients who have a phenotype which is not typical of Milroy disease is very small (<5%). For the 22 mutation positive patients, 14 novel VEGFR3 mutations were identified, two of which were in exon 22 and one in exon 17, confirming that these exons should be included in VEGFR3 analysis. No mutations were found outside the kinase domains, showing that analysis of this part of the gene is not useful for Milroy disease patients. VEGFC, which encodes the ligand for VEGFR3, was sequenced in all patients with typical Milroy disease (groups I and II) and no mutations were identified.
机译:Milroy疾病(I型遗传性淋巴水肿,MIM 153100)是先天性原发性淋巴水肿,具有常染色体显性遗传。已知血管内皮生长因子受体3(VEGFR3)(FLT4)基因突变会引起Milroy病,但对于原发性淋巴水肿患者,更具体地说是在具有类似Milroy表型的患者中,VEGFR3突变的发生率尚不确定疾病。这项研究旨在解决这个问题,从而描述Milroy疾病的表型。分析了52例原发性淋巴水肿患者VEGFR3编码区的突变。将患者分为四组:具有家族史的典型Milroy疾病(I组),没有家族史的典型Milroy疾病(II组),非典型Milroy疾病(III组)和复杂的原发性淋巴水肿(IV组)。结果表明,通过严格的表型分析,检测到VEGFR3突变的可能性得到了优化。在有家族史的典型Milroy患者中,突变发生率为75%(I组),如果阳性家族史不是诊断标准,则突变率为68%。阳性的家族史在Milroy疾病中不是必需的。在具有Milloy疾病非典型表型的患者中检测到VEGFR3突变的可能性非常小(<5%)。对于22例突变阳性患者,鉴定出14个新的VEGFR3突变,其中两个在外显子22中,一个在外显子17中,证实这些外显子应包括在VEGFR3分析中。在激酶结构域外未发现突变,表明对该基因部分的分析对Milroy病患者无用。在所有患有典型Milroy疾病的患者(I和II组)中对VEGFC编码的VEGFR3配体进行了测序,未发现突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号